文献速递心脏核医学肿瘤 PET/CT

多柔比星对心肌代谢的影响作为后续心脏毒性发生前提:一项转化型18F-FDG PET/CT观察研究

Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational 18F-FDG PET/CT Observation.
PubMed 文献 · J Nucl Med · 2017-06-23

该转化研究在小鼠中验证多柔比星剂量依赖性增加左心室葡萄糖代谢率,并回顾性分析69例接受多柔比星方案治疗的霍奇金病患者系列18F-FDG PET/CT,发现基线左心室SUV较低者后续心脏异常发生率更高,提示基线心肌FDG摄取可能预测化疗心脏毒性,作者认为需前瞻性临床试验验证。

要点

  • 小鼠中多柔比星剂量依赖性增加左心室葡萄糖代谢率,标准剂量和高剂量组均较对照显著升高。
  • 霍奇金病患者中11/36(31%)出现新发心脏异常,其治疗前左心室SUV显著低于其余患者(1.53±0.9 vs 3.34±2.54,P<0.01)。
  • 多因素分析证实基线左心室SUV对后续心脏异常具有预测价值,作者认为需前瞻性临床试验验证。

核心结论

  • 多柔比星剂量依赖性增加左心室葡萄糖代谢率,尤其在基线18F-FDG摄取较低时更为明显。
  • 霍奇金病患者开始多柔比星化疗前心肌18F-FDG摄取较低可能预测化疗诱导的心脏毒性发生,作者认为需前瞻性临床试验验证该假说。

研究设计与样本

  • 转化研究:15只无胸腺小鼠静脉给予生理盐水(n=5)或多柔比星5或7.5 mg/kg(各n=5),给药前后行动态小动物PET估算左心室葡萄糖代谢率。
  • 回顾性识别69例接受多柔比星、博来霉素、长春碱和达卡巴嗪方案成功治疗霍奇金病且完成4次连续18F-FDG PET/CT检查的患者,在左心室心肌勾画感兴趣区量化平均SUV。
  • 所有患者随后接受电话随访(中位随访30个月),其中36例同意接受心电图和经胸超声心动图检查。

主要发现

  • 小鼠基线左心室葡萄糖代谢率为17.9±4.4 nmol×min-1×g-1;多柔比星标准剂量组为27.9±9 nmol×min-1×g-1(P<0.05 vs 对照),高剂量组为37.2±7.8 nmol×min-1×g-1(P<0.01 vs 对照,P<0.05 vs 标准剂量组)。
  • 霍奇金病患者左心室SUV在多柔比星治疗期间进行性升高,并在随访时持续存在。
  • 36例患者中11例(31%)出现新发心脏异常,这些患者治疗前左心室SUV显著低于其余患者(1.53±0.9 vs 3.34±2.54,P<0.01)。
  • 多因素分析证实基线左心室SUV对后续心脏异常具有预测价值。

局限性

  • 原文结论指出,所提出的假说需前瞻性临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The present translational study aimed to verify whether serial 18F-FDG PET/CT predicts doxorubicin cardiotoxicity. Methods: Fifteen athymic mice were treated intravenously with saline (n = 5) or with 5 or 7.5 mg of doxorubicin per kilogram (n = 5 each) and underwent dynamic small-animal PET beforehand and afterward to estimate left ventricular (LV) metabolic rate of glucose (MRGlu). Thereafter, we retrospectively identified 69 patients who had been successfully treated with a regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin disease (HD) and had undergone 4 consecutive 18F-FDG PET/CT scans. Volumes of interest were drawn on LV myocardium to quantify mean SUV. All patients were subsequently interviewed by telephone (median follow-up, 30 mo); 36 of them agreed to undergo electrocardiography and transthoracic echocardiography. Results: In mice, LV MRGlu was 17.9 ± 4.4 nmol × min-1 × g-1 at baseline. Doxorubicin selectively and dose-dependently increased this value in the standard-dose (27.9 ± 9 nmol × min-1 × g-1, P < 0.05 vs. controls) and high-dose subgroups (37.2 ± 7.8 nmol × min-1 × g-1, P < 0.01 vs. controls, P < 0.05 vs. standard-dose). In HD patients, LV SUV showed a progressive increase during doxorubicin treatment that persisted at follow-up. New-onset cardiac abnormalities appeared in 11 of 36 patients (31%). In these subjects, pretherapy LV SUV was markedly lower with respect to the remaining patients (1.53 ± 0.9 vs. 3.34 ± 2.54, respectively, P < 0.01). Multivariate analysis confirmed the predictive value of baseline LV SUV for subsequent cardiac abnormalities. Conclusion: Doxorubicin dose-dependently increases LV MRGlu, particularly in the presence of low baseline 18F-FDG uptake. These results imply that low myocardial 18F-FDG uptake before the initiation of doxorubicin chemotherapy in HD patients may predict the development of chemotherapy-induced cardiotoxicity, suggesting that prospective clinical trials are warranted to test this hypothesis.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bauckneht M, Ferrarazzo G, Fiz F, et al. Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational 18F-FDG PET/CT Observation. J Nucl Med. 2017. PMID: 28646013. doi:10.2967/jnumed.117.191122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。